10 Best Penny Stocks to Buy for Long Term
The opportunity is not in buying every low-priced penny stock but rather in finding smaller companies where earnings, balance sheets, and business quality are improving faster than the market is giving...
Cytomx Therapeutics Inc. (CTMX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 15,013,093 | $70,561,537 | +68% | 4.35% |
| 2. | Perceptive Advisors Joseph Edelman | 10,098,824 | $47,464,473 | +5% | 0.93% |
| 3. | Point72 Asset Management Steve Cohen | 7,875,390 | $37,014,333 | +52% | 0.05% |
| 4. | Citadel Investment Group Ken Griffin | 5,406,193 | $25,409,107 | +1480% | 0% |
| 5. | Baker Bros. Advisors Julian Baker And Felix Baker | 4,975,826 | $23,386,382 | +18% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.55 | 5,000 | $7,750.00 | 5,142 | 2023-03-29 | Filing | |
| $10.33 | 9,000 | $92,970.00 | 9,979 | 2019-03-04 | Filing | |
| $12.00 | 3,000 | $36,000.00 | 3,000 | 2015-10-14 | Filing | |
| $12.00 | 5,000 | $60,000.00 | 5,000 | 2015-10-14 | Filing | |
| $12.00 | 5,000 | $60,000.00 | 5,000 | 2015-10-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.42 | 21,279 | $136,675.02 | 189,446 | 2026-03-17 | Filing | |
| $6.42 | 118,969 | $764,137.89 | 1,078,922 | 2026-03-17 | Filing | |
| $6.42 | 31,492 | $202,273.12 | 300,760 | 2026-03-17 | Filing | |
| $6.42 | 19,323 | $124,111.63 | 296,948 | 2026-03-17 | Filing | |
| $4.54 | 101,793 | $461,906.10 | 987,891 | 2025-11-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 31,955,637 | $150,191,494 | 0.01% | |
| 2. | 10,202,785 | $47,953,089 | 0% | |
| 3. | 9,982,124 | $46,915,983 | 1.75% | |
| 4. | 8,733,118 | $41,045,655 | 0% | |
| 5. | 5,663,408 | $26,618,018 | 0% |
News See All
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics First Quarter 2026 Financial Results Call.
9 Best Healthcare Penny Stocks to Buy According to Hedge Funds
Volatility in the equity market has been on another level in the first quarter of the year.
10 Stocks Under $5 That Will Explode
On April 8, 2026, in an interview with Reuters, Matt Stucky, chief portfolio manager for equities at Northwestern Mutual Wealth Management Company, discussed his inclination toward small- and mid-cap ...
10 Best Multibagger Penny Stocks to Invest In
Small-cap and penny stocks are often overlooked by Wall Street as they tend to be extremely volatile.
10 Popular Penny Stocks on Robinhood to Buy
Robinhood is a FINRA and SEC-regulated broker. It plays the role of a bridge that routes customer orders to market makers and exchanges.
11 Most Active Small Cap Stocks to Buy
Investing in small-cap stocks that are active in terms of average trading volume offers a balanced approach to capturing growth while managing some of the inherent risks associated with smaller companies...
Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating
On February 4, 2026, Barclays raised its price target on CytomX Therapeutics, Inc.
15 Best Small Cap Stocks to Buy According to Wall Street
Small-cap stocks are beginning to draw renewed attention in 2026 as investors reassess where the next leg of returns could come from.
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX)
TheFly reported on January 20 that Piper Sandler raised its price target on CTMX to $10 from $6.50, keeping an Overweight rating. The firm noted that Initial Phase 1 data for varsetatug maseatecan...
Hedge Fund Resource Center